FUSION Regimen: Combined Pro re Nata and Fixed Regimen Ranibizumab in Exudative Age-related Macular Degeneration

Inclusion Criteria: * subfoveal or juxtafoveal CNV owing to AMD, defined by fluorescein angiography (FA) * presence on SD-OCT of subretinal or intraretinal fluid associated or not with macular edema * Best corrected visual acuity (BCVA) in the study eye between 20/20 and 20/125, inclusive * total area of the lesion (including blood, neovascularization and scar/atrophy) of ≤8 disc areas, of which at least 50% must be active choroidal neovascularization (CNV) (defined as the neovascular component of the lesion as defined by FA * all angiographic subtypes \[predominantly classic, minimally classic and occult\] were eligible) * clear ocular media and adequate pupillary dilatation to allow collection of fundus photographs and FA of a sufficient quality to be analyzed * intraocular pressure of 21 mmHg or less * and no previous treatment for AMD Exclusion Criteria: * presence of scarring or atrophy \>75% of the total lesion size (patients with subfoveal scar or atrophy were excluded) * subretinal haemorrhage \>75% of the total lesion size; presence of serous retinal pigment epithelial detachments \>5 disc areas * presence of intraocular inflammation (≥ trace cell or flare), epiretinal membrane, macular hole or vitreous haemorrhage * history of idiopathic or autoimmune-associated uveitis in either eye * significant media opacities, including cataract, which might interfere with VA, assessment of toxicity or fundus photography in the study eye * presence of other causes of CNV, including pathological myopia (spherical equivalent of -3 diopters or more, or axial length of 25 mm or more, or fundus findings suggestive of pathologic myopia), ocular histoplasmosis syndrome, angioid streaks, choroidal rupture and multifocal choroiditis * any retinal treatment (aside from antioxidants), including (but not limited to) intravitreal injections, photodynamic therapy with verteporfin, laser photocoagulation or surgery * history of rhegmatogenous retinal detachment, pars plana vitrectomy or corneal transplant * and previous radiation in the region of the study eye.